Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / PPBP

PPBP

Basics

Aliases:
This biomarker is also known as:
  • leukocyte-derived growth factor,
  • pro-platelet basic protein,
  • LDGF,
  • CXC chemokine ligand 7,
  • B-TG1,
  • SCYB7,
  • PBP,
  • neutrophil-activating peptide 2,
  • macrophage-derived growth factor,
  • platelet basic protein,
  • TC2,
  • MDGF,
  • TC1,
  • pro-platelet basic protein (chemokine (C-X-C motif) ligand 7),
  • CTAPIII,
  • beta-thromboglobulin,
  • CXCL7,
  • connective tissue-activating peptide III,
  • neutrophil-activating peptide-2,
  • thrombocidin 1,
  • Beta-TG,
  • thromboglobulin, beta-1,
  • small inducible cytokine B7,
  • TGB,
  • LA-PF4,
  • small inducible cytokine subfamily B, member 7,
  • NAP-2-L1,
  • THBGB1,
  • thrombocidin 2,
  • THBGB,
  • low-affinity platelet factor IV,
  • NAP-2,
  • TGB1,
  • CTAP3,
  • CTAP-III,
  • b-TG1,

View in BioMuta

Description…

CTAP-III (officially named PPBP) is a platelet-derived growth factor that belongs to the CXC chemokine family. This growth factor is a potent chemoattractant and activator of neutrophils. It has been shown to stimulate various cellular processes including DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and sythesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by synovial cells.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: PPBP

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Three
QA State: Curated

Overview

CTAP-III was identified to be significantly higher in venous than in arterial blood. CTAP III levels decreased after lung tumor resection (P = .01). In two independent population cohorts, CTAP III was significantly associated with lung cancer. CTAP-III may also modify breast cancer cells and surrounding extracellular matrix to facilitate metastasis. In contrast to earlier findings from analyzes of postdiagnostically collected sera, the addition of 7 biomarkers (apolipoprotein A1 (APOA1), truncated transthyretin (TTR), transferrin (TF), hepcidin (HAMP), β-2 microglobulin B2M), connective tissue activating protein III (CTAPIII, a.k.a PPBP) to CA 125 did not improve sensitivity for preclinical diagnosis of ovarian cancer beyond CA 125 alone.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. CTAP-III, also known as PPBP, alone was not a strong predictor.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 02/12/2015

Please register for the 29th EDRN Steering Committee Meeting in Atlanta, GA from March 31-April 2, 2015. The registration page has information about booking hotel rooms and a draft agenda of the meeting.

Announcement